Steph & Co. Lowers Holdings in Kenvue Inc. (NYSE:KVUE)

Steph & Co. reduced its position in shares of Kenvue Inc. (NYSE:KVUE) by 2.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,980 shares of the company’s stock after selling 625 shares during the period. Steph & Co.’s holdings in Kenvue were worth $491,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. State Street Corp lifted its position in Kenvue by 16.8% during the third quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Kenvue by 8.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after buying an additional 7,115,374 shares in the last quarter. Holocene Advisors LP raised its position in shares of Kenvue by 75.5% during the 3rd quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after buying an additional 5,975,392 shares in the last quarter. M&G PLC lifted its holdings in shares of Kenvue by 538.0% during the 3rd quarter. M&G PLC now owns 4,341,172 shares of the company’s stock worth $99,847,000 after acquiring an additional 3,660,730 shares during the last quarter. Finally, FMR LLC grew its position in Kenvue by 2.3% in the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after acquiring an additional 3,075,019 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on KVUE. JPMorgan Chase & Co. lifted their price target on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Citigroup dropped their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Barclays upgraded shares of Kenvue to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and reduced their target price for the company from $25.00 to $24.00 in a report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Kenvue currently has an average rating of “Hold” and an average price target of $23.18.

Kenvue Trading Down 1.0 %

Shares of KVUE opened at $20.83 on Thursday. The stock has a market capitalization of $39.94 billion, a P/E ratio of 37.87, a PEG ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a fifty day simple moving average of $22.50 and a two-hundred day simple moving average of $21.64.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same period in the prior year, the business posted $0.31 earnings per share. Kenvue’s revenue for the quarter was down .4% on a year-over-year basis. On average, research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.